Pharmaceutical composition and method for the transdermal delivery of calcium

• US 20070292493A1
• Filed: 06/15/2006
• Published: 12/20/2007
• Est. Priority Date: 06/15/2006
• Status: Abandoned Application

• Current Assignee: Barbara T. Brierre
• Original Assignee: Barbara T. Brierre
• Inventors: Brierre, Barbara T.
• Application Number:
  US11/453,833
• Publication Number:
  US 20070292493A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/4188 condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/51 Thiamines, e.g. vitamin B1
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00

Abstract

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John'"'"'s wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

Claims

1. A transdermal pharmaceutical composition for reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency in a human comprising:

a therapeutically effective amount of a pharmaceutically acceptable salt of calcium; and

a pharmaceutically acceptable carrier comprising a pluronic lecithin organogel;

wherein a dosage of said composition is rubbed onto an outer layer of skin of said human to achieve said transdermal delivery of said therapeutically effective amount of said pharmaceutically acceptable salt of calcium.

2. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of calcium is in the range of 10 mg to 150 mg per dosage.

3. The transdermal pharmaceutical composition according to claim 2, wherein said therapeutically effective amount of calcium is 40 mg per dosage.

4. The transdermal pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable salt of calcium is calcium pantothenate.

5. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a pharmaceutically acceptable salt of a mineral selected from the group consisting of magnesium, zinc, selenium, manganese, chromium, and any combination thereof.

6. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a vitamin selected from the group consisting of vitamin A, vitamin D, vitamin C, vitamin E, vitamin B₆, vitamin B₁₂, vitamin B₃, vitamin B₅, vitamin B₂, vitamin B₁, folic acid, choline, lecithin, inositol, PABA, biotin, bioflavonoids, and any combination thereof.

7. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a carotenoid selected from the group consisting of lycopene, lutein, and a combination thereof.

8. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a hormone selected from the group consisting of dehydroepiandrosterone, progesterone, pregnenolone, melatonin, and any combination thereof.

9. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of an amino acid selected from the group consisting of arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, acetyl-l-carnitine, and any combination thereof.

10. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a fatty acid selected from the group consisting of a fish oil, a flax seed oil, and any combination thereof.

11. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of coenzyme Q10.

12. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a cartilage building nutrient selected from the group consisting of glucosamine, chondroitin, MSM, and any combination thereof.

13. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a herb selected from the group consisting of ginkgo biloba, echinacea, 5-HTP, St. John'"'"'s wort, saw palmetto, and any combination thereof.

14. The transdermal pharmaceutical composition according to claim 1, wherein said pluronic lecithin organogel comprises a mixture of a soy lecithin/isopropyl palmitate and a pluronic organogel.

15. The transdermal pharmaceutical composition according to claim 1, wherein said imbalances caused by calcium deficiency are selected from the group consisting of hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

16. A transdermal pharmaceutical composition for reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency in a human comprising:

a therapeutically effective amount of calcium pantothenate;

a therapeutically effective amount of magnesium chloride; and

a pharmaceutically acceptable carrier comprising a pluronic lecithin organogel;

wherein a dosage of said composition is rubbed onto an outer layer of skin of said human to achieve said transdermal delivery of said therapeutically effective amount of said calcium pantothenate and said magnesium chloride.

17. The transdermal pharmaceutical composition according to claim 16, wherein said therapeutically effective amount of said calcium pantothenate is in the range of 10 mg to 150 mg per dosage and said therapeutically effective amount of said magnesium chloride is in the range of 4.0 to 100 mg per dosage.

18. The transdermal pharmaceutical composition according to claim 17, wherein said therapeutically effective amount of said calcium pantothenate is 40 mg per dosage and said therapeutically effective amount of said magnesium chloride is 7.44 mg per dosage.

19. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a pharmaceutically acceptable salt of a mineral selected from the group consisting of zinc, selenium, manganese, chromium, and any combination thereof.

20. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a vitamin selected from the group consisting of vitamin A, vitamin D, vitamin C, vitamin E, vitamin B₆, vitamin B₁₂, vitamin B₃, vitamin B₅, vitamin B₂, vitamin B₁, folic acid, choline, lecithin, inositol, PABA, biotin, bioflavonoids, and any combination thereof.

21. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a carotenoid selected from the group consisting of lycopene, lutein, and a combination thereof.

22. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a hormone selected from the group consisting of dehydroepiandrosterone, progesterone, pregnenolone, melatonin, and any combination thereof.

23. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of an amino acid selected from the group consisting of arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, acetyl-l-carnitine, and any combination thereof.

24. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a fatty acid selected from the group consisting of a fish oil, a flax seed oil, and a combination thereof.

25. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of coenzyme Q10.

26. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a cartilage building nutrient selected from the group consisting of glucosamine, chondroitin, MSM, and any combination thereof.

27. The transdermal pharmaceutical composition according to claim 16, further comprising a therapeutically effective amount of a herb selected from the group consisting of ginkgo biloba, echinacea, 5-HTP, St. John'"'"'s wort, saw palmetto, and any combination thereof.

28. The transdermal pharmaceutical composition according to claim 16, wherein said pluronic lecithin organogel comprises a mixture of a soy lecithin/isopropyl palmitate and a pluronic organogel.

29. The transdermal pharmaceutical composition according to claim 16, wherein said imbalances caused by calcium deficiency are selected from the group consisting of hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

30. A method of reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency in a human comprising the steps of topically administering to said human a transdermal pharmaceutical composition comprising:

a therapeutically effective amount of a pharmaceutically acceptable salt of calcium; and

a pharmaceutically acceptable carrier comprising a pluronic lecithin organogel;

wherein a dosage of said composition is rubbed onto an outer layer of skin of said human to achieve said transdermal delivery of said therapeutically effective amount of said pharmaceutically acceptable salt of calcium.

31. The method according to claim 30, wherein said therapeutically effective amount of calcium is in the range of 10 mg to 150 mg per dosage.

32. The method according to claim 31, wherein therapeutically effective amount of calcium is 40 mg per dosage.

33. The method according to claim 30, wherein said pharmaceutically acceptable salt of calcium is calcium pantothenate.

34. The method according to claim 30, further comprising a therapeutically effective amount of a pharmaceutically acceptable salt of a mineral selected from the group consisting of magnesium, zinc, selenium, manganese, chromium, and any combination thereof.

35. The method according to claim 30, further comprising a therapeutically effective amount of a vitamin selected from the group consisting of vitamin A, vitamin D, vitamin C, vitamin E, vitamin B₆, vitamin B₁₂, vitamin B₃, vitamin B₅, vitamin B₂, vitamin B₁, folic acid, choline, lecithin, inositol, PABA, biotin, bioflavonoids, and any combination thereof.

36. The method according to claim 30, further comprising a therapeutically effective amount of a carotenoid selected from the group consisting of lycopene, lutein, and a combination thereof.

37. The method according to claim 30, further comprising a therapeutically effective amount of a hormone selected from the group consisting of dehydroepiandrosterone, progesterone, pregnenolone, melatonin, and any combination thereof.

38. The method according to claim 30, further comprising a therapeutically effective amount of an amino acid selected from the group consisting of arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, acetyl-l-carnitine, and any combination thereof.

39. The method according to claim 30, further comprising a therapeutically effective amount of a fatty acid selected from the group consisting of a fish oil, a flax seed oil, and a combination thereof.

40. The method according to claim 30, further comprising a therapeutically effective amount of coenzyme Q10.

41. The method according to claim 30, further comprising a therapeutically effective amount of a cartilage building nutrient selected from the group consisting of glucosamine, chondroitin, MSM, and any combination thereof.

42. The method according to claim 30, further comprising a therapeutically effective amount of a herb selected from the group consisting of ginkgo biloba, echinacea, 5 HTP, St. John'"'"'s wort, saw palmetto, and any combination thereof.

43. The method according to claim 30, wherein said pluronic lecithin organogel comprises a mixture of a soy lecithin/isopropyl palmitate and a pluronic organogel.

44. The method according to claim 30, wherein said imbalances caused by calcium deficiency are selected from the group consisting of hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.